Skip Navigation

This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (54)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Meriggiola, M. C.
Right arrow Articles by Flamigni, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meriggiola, M. C.
Right arrow Articles by Flamigni, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol 13, 1225-1229, Copyright © 1998 by Oxford University Press

ARTICLES

Low dose of cyproterone acetate and testosterone enanthate for contraception in men

MC Meriggiola, WJ Bremner, A Costantino, G Di Cintio and C Flamigni
Department of Obstetrics and Gynecology and Core Lab, S.Orsola Hospital, University of Bologna, Italy.

After a control phase, 10 normal men received cyproterone acetate (CPA) at a dose of 25 mg/day (CPA-25; n=5) or 12.5 mg/day (CPA-12.5; n=5) plus testosterone enanthate (TE) 100 mg/week, for 16 weeks. Throughout the study sperm counts were performed every 2 weeks, and luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone, biochemical and haematological tests were performed every 4 weeks. All five men in group CPA-25 and three men in group CPA-12.5 achieved azoospermia. One man in group CPA-25 was azoospermic by week 12 of hormone administration, but had a sperm count of 0.1 x 10(6)/ml at week 16. Time to azoospermia was 9.0+/-1.3 and 8.7+/-0.7 weeks in groups CPA- 25 and CPA-12.5 respectively. Gonadotrophins were decreased by week 4 of hormone administration, remained around the minimum detectability of the assay for the duration of hormone administration and returned to baseline after stopping hormone administration. Testosterone values did not change. No change in any biochemical parameters was found. Haematological parameters were decreased at week 16 of hormone administration and returned to baseline after stopping hormone administration. In conclusion, these results suggest that an hormonal regimen consisting of testosterone plus a progestin with anti- androgenic properties holds promise as an effective, safe and reversible male contraceptive.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
S. T. Page, J. K. Amory, and W. J. Bremner
Advances in Male Contraception
Endocr. Rev., June 1, 2008; 29(4): 465 - 493.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Y. Liu, R. S. Swerdloff, B. D. Anawalt, R. A. Anderson, W. J. Bremner, J. Elliesen, Y.-Q. Gu, W. M. Kersemaekers, Robert. I. McLachlan, M. C. Meriggiola, et al.
Determinants of the Rate and Extent of Spermatogenic Suppression during Hormonal Male Contraception: An Integrated Analysis
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1774 - 1783.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
K. L. Matthiesson and R. I. McLachlan
Male hormonal contraception: concept proven, product in sight?
Hum. Reprod. Update, July 1, 2006; 12(4): 463 - 482.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
B.M. Brady, J.K. Amory, A. Perheentupa, M. Zitzmann, C.J. Hay, D. Apter, R.A. Anderson, W.J. Bremner, P. Pollanen, E. Nieschlag, et al.
A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive
Hum. Reprod., January 1, 2006; 21(1): 285 - 294.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. J. Hay, B. M. Brady, M. Zitzmann, K. Osmanagaoglu, P. Pollanen, D. Apter, F. C. W. Wu, R. A. Anderson, E. Nieschlag, P. Devroey, et al.
A Multicenter Phase IIb Study of a Novel Combination of Intramuscular Androgen (Testosterone Decanoate) and Oral Progestogen (Etonogestrel) for Male Hormonal Contraception
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2042 - 2049.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
A. D. Coviello, W. J. Bremner, A. M. Matsumoto, K. L. Herbst, J. K. Amory, B. D. Anawalt, X. Yan, T. R. Brown, W. W. Wright, B. R. Zirkin, et al.
Intratesticular Testosterone Concentrations Comparable With Serum Levels Are Not Sufficient to Maintain Normal Sperm Production in Men Receiving a Hormonal Contraceptive Regimen
J Androl, November 1, 2004; 25(6): 931 - 938.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
B.M. Brady, M. Walton, N. Hollow, A.T. Kicman, D.T. Baird, and R.A. Anderson
Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception
Hum. Reprod., November 1, 2004; 19(11): 2658 - 2667.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
Y.-L. Gui, C.-H. He, J. K. Amory, W. J. Bremner, E-X. Zheng, J. Yang, P.-J. Yang, and E.-S. Gao
Male Hormonal Contraception: Suppression of Spermatogenesis by Injectable Testosterone Undecanoate Alone or With Levonorgestrel Implants in Chinese Men
J Androl, September 1, 2004; 25(5): 720 - 727.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. I. McLachlan, D. M. Robertson, E. Pruysers, A. Ugoni, A. M. Matsumoto, B. D. Anawalt, W. J. Bremner, and C. Meriggiola
Relationship between Serum Gonadotropins and Spermatogenic Suppression in Men Undergoing Steroidal Contraceptive Treatment
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 142 - 149.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. C. Meriggiola, A. Costantino, S. Cerpolini, W. J. Bremner, D. Huebler, A. M. Morselli-Labate, B. Kirsch, A. Bertaccini, C. Pelusi, and G. Pelusi
Testosterone Undecanoate Maintains Spermatogenic Suppression Induced by Cyproterone Acetate Plus Testosterone Undecanoate in Normal Men
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5818 - 5826.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. von Eckardstein, G. Noe, V. Brache, E. Nieschlag, H. Croxatto, F. Alvarez, A. Moo-Young, I. Sivin, N. Kumar, M. Small, et al.
A Clinical Trial of 7{alpha}-Methyl-19-Nortestosterone Implants for Possible Use as a Long-Acting Contraceptive for Men
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5232 - 5239.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
M. C. Meriggiola, T. M.M. Farley, and M. T. Mbizvo
A Review of Androgen-Progestin Regimens for Male Contraception
J Androl, July 1, 2003; 24(4): 466 - 483.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. A. Anderson and D. T. Baird
Male Contraception
Endocr. Rev., December 1, 2002; 23(6): 735 - 762.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
R.A. Anderson, Z.M. van der Spuy, O.A. Dada, S.K. Tregoning, P.M. Zinn, O.A. Adeniji, T.A. Fakoya, K.B. Smith, and D.T. Baird
Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone
Hum. Reprod., November 1, 2002; 17(11): 2869 - 2877.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
M. C. Meriggiola, A. Costantino, W. J. Bremner, and A. M. Morselli-Labate
Higher Testosterone Dose Impairs Sperm Suppression Induced by a Combined Androgen-Progestin Regimen
J Androl, September 1, 2002; 23(5): 684 - 690.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. T. G. Gonzalo, R. S. Swerdloff, A. L. Nelson, B. Clevenger, R. Garcia, N. Berman, and C. Wang
Levonorgestrel Implants (Norplant II) for Male Contraception Clinical Trials: Combination with Transdermal and Injectable Testosterone
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3562 - 3572.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. A. Anderson, D. Kinniburgh, and D. T. Baird
Suppression of Spermatogenesis by Etonogestrel Implants with Depot Testosterone: Potential for Long-Acting Male Contraception
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3640 - 3649.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. C. Meriggiola, W. J. Bremner, A. Costantino, A. Bertaccini, A. M. Morselli-Labate, D. Huebler, G. Kaufmann, M. Oettel, and C. Flamigni
Twenty-One Day Administration of Dienogest Reversibly Suppresses Gonadotropins and Testosterone in Normal Men
J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2107 - 2113.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Kamischke, T. Heuermann, K. Kruger, S. von Eckardstein, I. Schellschmidt, A. Rubig, and E. Nieschlag
An Effective Hormonal Male Contraceptive Using Testosterone Undecanoate with Oral or Injectable Norethisterone Preparations
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 530 - 539.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W. M. Hair, K. Kitteridge, D. B. O'Connor, and F. C. W. Wu
A Novel Male Contraceptive Pill-Patch Combination: Oral Desogestrel and Transdermal Testosterone in the Suppression of Spermatogenesis in Normal Men
J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5201 - 5209.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
D. J. Handelsman, S. Wishart, and A. J. Conway
Oestradiol enhances testosterone-induced suppression of human spermatogenesis
Hum. Reprod., March 1, 2000; 15(3): 672 - 679.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Kamischke, S. Venherm, D. Plöger, S. von Eckardstein, and E. Nieschlag
Intramuscular Testosterone Undecanoate and Norethisterone Enanthate in a Clinical Trial for Male Contraception
J. Clin. Endocrinol. Metab., January 1, 2000; 86(1): 303 - 309.
[Abstract] [Full Text]

Home page
 Hum ReprodHome page
G. Noe, J. Suvisaari, C. Martin, A.J. Moo-Young, K. Sundaram, S.I. Saleh, E. Quintero, H.B. Croxatto, and P. Lahteenmaki
Gonadotrophin and testosterone suppression by 7{alpha}-methyl-19-nortestosterone acetate administered by subdermal implant to healthy men
Hum. Reprod., September 1, 1999; 14(9): 2200 - 2206.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.